© American Cancer Society
Supplements: Policy and Instructions
Cancer Cytopathology publishes Supplements on various topics deemed to be of interest to the readership of the journal and that have significant educational value.
Please note: The journal will not consider supplements focusing on a single drug.
Responsible member(s) of the organizing group who wish to publish their proceedings or monographs as a Supplement shall identify a Publication Committee and a corresponding individual to whom the Cancer Cytopathology Editorial Office will direct communications. The Publication Committee shall submit a proposal in writing to the Cancer Cytopathology Editorial Office prior to the meeting and prior to the selection of those who will submit manuscripts containing the following information:
- Name and date of the meeting,
- Sponsor(s) of the meeting and supplement (financial support),
- Number of articles and topics,
- Speakers and their affiliations,
- Estimated page count, and
- Name and address of corresponding individual.
The Publication Committee must certify the absence of financial interest or bias (either competitive or amiable) in the selection of manuscripts. The Editor-in-Chief of the journal will review a proposal and render a decision on whether it seems appropriate for the journal. If a proposal is approved “in concept,” that does not guarantee that any or all submitted manuscripts will be published in the journal. It simply means that the concept for the supplement appears to be of interest to the journal given the preliminary information provided.
If the supplement is approved “in concept,” pricing information will be sent by the journal publisher to the corresponding individual on the Publication Committee. It is the responsibility of the Publication committee to communicate pricing and get expense approval from the sponsor of the supplement. When the supplement is submitted, written confirmation will be requested from the Supplement Publication Committee and/or sponsor indicating intent to pay.
Responsibilities of the Supplement Publication Committee
The Supplement Publication Committee is responsible for collecting all manuscripts, ensuring that manuscripts comply with Cancer Cytopathology's Instructions for Authors , and conducting the initial review of each manuscript. The Publication Committee will designate a Corresponding Member to be the liaison to the Cancer Cytopathology Editorial Office.
The corresponding author of a manuscript to be published in a Supplement must submit the manuscript to the Publication Committee. Manuscripts prematurely submitted to the Cancer Cytopathology Editorial Office will be returned without review. The Publication Committee must inform the author of its mailing address if mailing is necessary. Manuscripts presented at a meeting must be received by the Publication Committee no later than the day of the presentation. Work-group-type reports produced during a meeting can be submitted to the Publication Committee at the end of the meeting, but no later than two weeks after the conclusion of the meeting. Any work-group reports should be formatted as articles with authors (please see Instructions for Authors, for group authorship guidelines), abstracts, and key words. Supplements may contain Original Articles, Reviews, and other types of educational presentations. All manuscripts submitted must be in standard paper format. Transcripts will not be considered.
Supplements submitted to Cancer Cytopathology well beyond the meeting date will be reviewed again for appropriateness. Topics considered no longer relevant may be rejected.
Peer Review by the Publication Committee
If approved by the Managing Editor, the Publication Committee may arrange for peer review of the manuscripts. The names and addresses of all reviewers must be submitted to the Cancer Cytopathology Editorial Office at the time of submission. Reviewers of manuscripts must complete the standard Cancer Cytopathology "Supplement Reviewer Form" which will be provided by the Editorial Office to the Publication Committee upon request. The review process, including revisions of manuscripts, must be completed within 30 days after the end of the meeting (there may be up to a two-week extension for work-group-type manuscripts). Manuscripts, along with the completed Supplement Reviewer Forms, must be submitted to Cancer Cytopathology by the Publication Committee immediately following the completion of the review process. Manuscripts rejected by the Publication Committee should not be forwarded to the Cancer Cytopathology Editorial Office. If the review completed by the Publications Committee is deemed inadequate by journal editors, the Cancer Cytopathology Editorial Office will coordinate another round of peer-review.
The review process described above will facilitate expeditious publication of a Supplement. It is obviously inappropriate to delay publication of the proceedings of a meeting because a single or a few authors did not conform to the above policy. Therefore, each potential author must be informed of and accept this policy as a condition of participation in the meeting, prior to her/his formal acceptance of the program. The Editor-in-Chief may elect to assign additional reviewers. The final decision on publication of a supplement or individual manuscript is made by the Editor-in-Chief.
Peer Review by Cancer Cytopathology
If the publication committee does not wish to facilitate peer review, unreviewed manuscripts may be submitted to Cancer Cytopathology. In this case, the Editor-in-Chief of the journal will assign a responsible Section or Guest Editor to oversee the peer-review process. The publication committee must provide a list of recommended reviewers. Cancer Cytopathology Editors are not required to use these suggested reviewers.
The peer review will be completed as per normal journal paper processing with reviews and decisions sent directly to the correspondent. Once all the manuscripts submitted with the supplement are final, the publication committee correspondent will be notified and those manuscripts approved will be forwarded for publication. Note: Nothing will be sent to the publisher until all the pieces are final.
Please note: The Cancer Cytopathology Editorial Office cannot estimate when a Supplement will actually be published. The publication date is not confirmed until all author page proofs are returned.
Submitting Final Manuscripts to Cancer Cytopathology
The Corresponding Member of the Publications Committee will transfer “en bloc” the manuscripts to be considered for publication. Final manuscripts must be submitted online through ScholarOne Manuscripts. The article type and section should be “supplement” and the cover letter should provide a statement identifying the supplement.
The following materials must be sent to the Cancer Cytopathology Editorial Office: copies of all reviewer forms completed, if applicable, that clearly indicate which papers that review correlates to, and “Conflict of Interest Disclosure Statement” form for each manuscript signed by every author on that manuscript, any and all written and signed permission forms obtained for the reproduction of previously published figures and tables, and a listing of all manuscripts to be included in the supplement (with authors noted) and in the order that the manuscripts should appear in print.
If you have any questions, please contact:
Cancer Cytopathology Editorial Office
American Cancer Society
250 Williams St.
Atlanta, GA 30303